The effects of forskolin and rolipram on cAMP, cGMP and free fatty acid levels in diet induced obesity

References

• Agarwal KC, Parks RE Jr (1983). Forskolin: a potential antimetastatic agent. Int. J. Cancer 32: 801–804.
   PubMed Web of Science ®Google Scholar
• Allen DO, Ahmed B, Naseer K (1986). Relationships between cyclic AMP levels and lipolysis in fat cells after isoproterenol and forskolin stimulation. J. Pharmacol. Exp. Ther. 238: 659–664.
   PubMedGoogle Scholar
• Badmaev V MM, Conte AA, Parker JE (2002). Diterpene forskolin (Coleus forskohlii Benth.): a possible new compound for reduction of body weight by increasing lean body mass. NutraCos 1: 6–7.
   Google Scholar
• Bristow MR, Ginsburg R, Strosberg A, Montgomery W, Minobe W (1984). Pharmacology and inotropic potential of forskolin in the human heart. J. Clin. Invest. 74: 212–223.
   PubMedGoogle Scholar
• Burns TW, Langley PE, Terry BE, Bylund DB, Forte LR Jr (1987). Comparative effects of forskolin and isoproterenol on the cyclic AMP content of human adipocytes. Life Sci. 40: 145–154.
   PubMedGoogle Scholar
• Carmen GY, Victor SM (2006). Signalling mechanisms regulating lipolysis. Cell Signal. 18: 401–408.
   PubMed Web of Science ®Google Scholar
• Ford ES, Mokdad AH (2008). Epidemiology of obesity in the western hemisphere. J. Clin. Endocrinol. Metab. 93, Suppl. 1: S1–S8.
   PubMed Web of Science ®Google Scholar
• Francis SH, Turko IV, Corbin JD (2001). Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucl. Acid Res. Mol. Biol. 65: 1–52.
   PubMed Web of Science ®Google Scholar
• Gao L, Niu Y, Liu W, Xie M, Liu X, Chen Z, Li L (2008). The antilipolytic action of bis(alpha-furancarboxylato)oxovanadium(IV) in adipocytes. Clin. Chim. Acta 388: 89–94.
   PubMed Web of Science ®Google Scholar
• Ghibaudi L, Cook J, Farley C, van Heek M, Hwa JJ (2002). Fat intake affects adiposity, co-morbidity factors, and energy metabolism of Sprague-Dawley rats. Obes. Res. 10: 956–963.
   PubMedGoogle Scholar
• Godard MP, Johnson BA, Richmond SR (2005). Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Obes. Res. 13: 1335–1343.
   PubMedGoogle Scholar
• Hanoune J, Defer N (2001). Regulation and role of adenylyl cyclase isoforms. Ann. Rev. Pharmacol. Toxicol. 41: 145–174.
   PubMed Web of Science ®Google Scholar
• Henderson S, Magu B, Rasmussen C, Lancaster S, Kerksick C, Smith P, Melton C, Cowan P, Greenwood M, Earnest C, Almada A, Milnor P, Magrans T, Bowden R, Ounpraseuth S, Thomas A, Kreider RB (2005). Effects of Coleus forskohlii supplementation on body composition and hematological profiles in mildly overweight women. J. Int. Soc. Sports Nutr. 2: 54–62.
   PubMedGoogle Scholar
• Iwatsubo K, Tsunematsu T, Ishikawa Y (2003). Isoform-specific regulation of adenylyl cyclase: a potential target in future pharmacotherapy. Exp. Opin. Ther. Targ. 7: 441–451.
   PubMed Web of Science ®Google Scholar
• Karpe F, Dickmann JR, Frayn KN (2011). Fatty acids, obesity, and insulin resistance: time for a re-evaluation. Diabetes 60: 2441–2449.
   PubMed Web of Science ®Google Scholar
• Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS (2002). Obesity and the risk of heart failure. N. Engl. J. Med. 347: 305–313.
   PubMed Web of Science ®Google Scholar
• Kralisch S, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M (2006). Tissue inhibitor of metalloproteinase 1 expression and secretion are induced by beta-adrenergic stimulation in 3T3-L1 adipocytes. J. Endocrinol. 189: 665–670.
   PubMed Web of Science ®Google Scholar
• Lafontan M, Berlan M (1993). Fat cell adrenergic receptors and the control of white and brown fat cell function. J. Lipid Res. 34: 1057–1091.
   PubMed Web of Science ®Google Scholar
• Laliberte F, Han Y, Govindarajan A, Giroux A, Liu S, Bobechko B, Lario P, Bartlett A, Gorseth E, Gresser M, Huang Z (2000). Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry 39: 6449–6458.
   PubMedGoogle Scholar
• Lieberman S (2004). A new potential weapon for fighting obesity. forskolin-the active diterpene in Coleus. Alt. Comple. Ther. 10: 330–333.
   Google Scholar
• Litosch I, Hudson TH, Mills I, Li SY, Fain JN (1982). Forskolin as an activator of cyclic AMP accumulation and lipolysis in rat adipocytes. Mol. Pharmacol. 22: 109–115.
   Google Scholar
• Nakamura J, Okamura N, Kawakami Y (2004). Augmentation of lipolysis in adipocytes from fed rats, but not from starved rats, by inhibition of rolipram-sensitive phosphodiesterase 4. Arch. Biochem. Biophys. 425: 106–114.
   PubMedGoogle Scholar
• Nicholson CD, Challiss RA, Shahid M (1991). Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci. 12: 19–27.
   PubMed Web of Science ®Google Scholar
• Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH (2012). Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421–433.
   PubMed Web of Science ®Google Scholar
• Schmitz-Peiffer C, Reeves ML, Denton RM (1992). Characterization of the cyclic nucleotide phosphodiesterase isoenzymes present in rat epididymal fat cells. Cell Signal. 4: 37–49.
   PubMedGoogle Scholar
• Selassie M, Sinha AC (2011). The epidemiology and aetiology of obesity: a global challenge. Best Pract. Res. Clin. Anaesthesiol. 25: 1–9.
   PubMedGoogle Scholar
• Snyder PB, Esselstyn JM, Loughney K, Wolda SL, Florio VA (2005). The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis. J. Lipid Res. 46: 494–503.
   PubMed Web of Science ®Google Scholar
• Strassheim D, Houslay MD, Milligan G (1992). Regulation of cardiac adenylate cyclase activity in rodent models of obesity. Biochem. J. 283: 203–208.
   PubMedGoogle Scholar
• Tang WJ, Hurley JH (1998). Catalytic mechanism and regulation of mammalian adenylyl cyclases. Mol. Pharmacol. 54: 231–240.
   PubMedGoogle Scholar
• Tesmer JJ, Sunahara RK, Gilman AG, Sprang SR (1997). Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha. GTPgammaS. Science 278: 1907–1916.
   PubMed Web of Science ®Google Scholar
• Wang H, Edens NK (2007). mRNA expression and antilipolytic role of phosphodiesterase 4 in rat adipocytes in vitro. J. Lipid Res. 48: 1099–1107.
   PubMed Web of Science ®Google Scholar
• Zhang R, Maratos-Flier E, Flier JS (2009). Reduced adiposity and high fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology 150: 3076–3082.
   PubMed Web of Science ®Google Scholar